Daré Bioscience (DARE) AI Stock Analysis

• Market Cap: $24.40M
• Dividend Yield: N/A
• Average Volume (3M): 170.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 13,479,502
• 10 Day Avg. Volume: 281,723
• 30 Day Avg. Volume: 170,743
• PEG Ratio: 0.07
• Price to Book (P/B): -4.41
• Price to Sales (P/S): 2709.59
• P/FCF Ratio: 5.50
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 3.72K
• Enterprise Value/Gross Profit: -1.41
• Enterprise Value/Ebitda: -1.53
• 1Y Price Target: $10.00
• Price Target Upside: 452.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $1.50 ▼(-17.13% Downside)

Daré Bioscience's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's ongoing financial distress, including negative equity and high liabilities, poses significant risks. Additionally, the stock's technical indicators suggest bearish momentum, further weighing down the score. While the earnings call provided some positive insights into the company's strategic initiatives, these are not enough to offset the financial and technical challenges.

Positive Factors

Product Pipeline Advancements

The upcoming launch of DARE to PLAY Sildenafil Cream signifies progress in Daré's product pipeline, enhancing its market position in women's health.

Strategic Partnerships

Partnerships like the one with the Gates Foundation provide strategic support and potential funding, strengthening Daré's R&D capabilities.

Grant-Funded Programs

Non-dilutive funding supports Daré's contraceptive development, reducing financial strain and enabling focus on innovation.

Negative Factors

Financial Instability

Negative equity and high liabilities pose a risk to Daré's financial stability, potentially impacting its ability to fund operations long-term.

Unprofitability

Persistent unprofitability challenges Daré's ability to sustain operations without external funding, impacting long-term viability.

Limited Capital Generation

Restrictions on capital generation limit Daré's financial flexibility, affecting its capacity to invest in growth and innovation.

Daré Bioscience Business Overview & Revenue Model

Company Description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

How the Company Makes Money

Daré Bioscience generates revenue primarily through a combination of product sales, licensing agreements, and collaborations with larger pharmaceutical companies. The company's revenue model includes potential milestones and royalties from its strategic partnerships, as well as funding from government grants and other research institutions aimed at supporting women's health initiatives. Successful clinical trial outcomes can lead to partnerships with larger entities, which may provide significant upfront payments and ongoing royalties from the commercialization of products developed through these collaborations.

Daré Bioscience Financial Statement Overview

Summary

Daré Bioscience faces significant financial challenges, including persistent unprofitability, negative equity, and high liabilities, indicating financial distress. Despite a recent positive trend in cash flow and revenue growth, the company's long-term sustainability remains questionable without a turnaround in profitability and a more stable balance sheet.

Income Statement

Daré Bioscience has struggled with profitability, as evidenced by consistently negative net income over the years. While there was a notable increase in revenue in 2024, the gross profit margin remains 100% due to revenue equaling gross profit, but this is overshadowed by significant negative EBIT and EBITDA margins, indicating high operational costs. The revenue growth from 2023 to 2024 is positive, which is a good sign, but the company remains unprofitable overall.

Balance Sheet

The balance sheet reveals a worrying situation with negative stockholders' equity, indicating financial instability. Additionally, the debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged with total liabilities exceeding total assets. The negative equity ratio suggests insolvency risk, which is a significant concern for stakeholders.

Cash Flow

While Daré Bioscience has managed to generate a positive operating cash flow in 2024, indicating some operational efficiency, the free cash flow remains inconsistent over the years. The positive free cash flow to net income ratio in 2024 is a positive indicator, but the historical volatility in cash flows points to potential financial management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.52K	9.78K	2.81M	10.00M	0.00	0.00
Gross Profit	-17.19M	-14.30M	-18.83M	-20.14M	-100.00K	-83.33K
EBITDA	-15.91M	-23.41M	-30.70M	-31.36M	-39.04M	-27.36M
Net Income	-17.46M	-4.05M	-30.16M	-30.95M	-38.70M	-27.40M
Balance Sheet
Total Assets	30.75M	22.10M	21.28M	43.83M	55.81M	7.55M
Cash, Cash Equivalents and Short-Term Investments	23.08M	15.70M	10.48M	34.67M	51.67M	4.67M
Total Debt	2.93M	1.30M	1.40M	488.74K	270.55K	756.84K
Total Liabilities	27.89M	28.11M	26.33M	32.71M	17.05M	8.70M
Stockholders Equity	2.86M	-6.01M	-5.05M	11.11M	38.75M	-1.15M
Cash Flow
Free Cash Flow	-6.85M	4.82M	-39.49M	-18.15M	-28.78M	-25.25M
Operating Cash Flow	-6.10M	5.39M	-38.86M	-18.09M	-28.76M	-25.23M
Investing Cash Flow	-741.49K	-573.05K	-629.43K	-63.07K	-14.52K	-17.63K
Financing Cash Flow	18.72M	433.83K	15.64M	1.34M	75.85M	25.13M

Daré Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Negative. The current price of 1.81 is below the 20-day moving average (MA) of 1.83, below the 50-day MA of 2.00, and below the 200-day MA of 2.53, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 46.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DARE.

Daré Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PASG	44 Neutral	$24.14M	―	-87.18%	―	―	38.42%
BOLD	40 Underperform	$24.85M	―	-44.88%	―	―	-0.50%
DARE	38 Underperform	$24.40M	-4.10	―	―	―	―
HIND	37 Underperform	$29.01M	―	-565.18%	―	-48.74%	89.18%
NRSN	30 Underperform	$25.59M	-1.78	―	―	―	31.09%

Daré Bioscience Corporate Events

Daré Bioscience Advances Women’s Health Innovations

Daré Bioscience is a health biotech company focused on advancing women’s health solutions through innovative science and real-world applications, operating primarily in the women’s health sector.

Daré Bioscience Advances Progesterone Delivery Study for Preterm Birth Prevention

Daré Bioscience, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is conducting a study titled ‘An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone Intravaginal Ring (IVR) 8 mg and 12 mg/Day Versus Progesterone Vaginal Insert 100mg.’ The study aims to compare how different progesterone delivery methods affect hormone levels in the body, focusing on potential treatments for preterm birth.

Daré Bioscience’s Ovaprene Study: A New Era in Contraceptive Innovation

Daré Bioscience is currently conducting a pivotal clinical study titled ‘A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene.’ The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene, a non-hormonal intravaginal ring. This research is significant as it explores a novel contraceptive option that could expand choices for women seeking non-hormonal methods.

Daré Bioscience Engages Market with New Presentation

Daré Bioscience, Inc. announced that it will use a corporate presentation dated September 2, 2025, in various meetings with securities market participants. The presentation will be available on the company’s website in the ‘Investors’ section, indicating a strategic move to engage with stakeholders and potentially enhance its market presence.

The most recent analyst rating on (DARE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Daré Bioscience’s Earnings Call: Optimism Amid Challenges

In the recent earnings call, Daré Bioscience expressed an optimistic outlook, highlighting significant progress in their dual-path strategy and upcoming product launches. Despite technical difficulties and a working capital deficit, the company remains focused on future growth, aiming to drive revenue and expand its market presence.

Daré Bioscience Announces Q2 2025 Financial Results

Daré Bioscience is a biopharmaceutical company focused on addressing unmet needs in women’s health through innovative solutions in areas such as contraception, sexual health, and menopause.